HCPLive Network

Cell-Cycle Progression Panel Identifies Prostate Cancer Risk

THURSDAY, March 28 (HealthDay News) -- The cell-cycle progression (CCP) gene panel is useful to improve the risk stratification for men with even low-risk, clinically localized prostate cancer, according to research published online March 4 in the Journal of Clinical Oncology.

Matthew R. Cooperberg, MD, MPH, of the University of California in San Francisco, and colleagues sought to validate a previously described genetic risk score called CCP (that provides a value calculated from the average expression of 31 CCP genes) and its ability to improve risk stratification in men with localized prostate cancer and predict recurrence after prostatectomy.

The researchers found that for each increase of one unit in the CCP score, the hazard ratio increased by 1.7, after adjusting for the patient's Cancer of the Prostate Risk Assessment Post-Surgical (CAPRA-S) score. Combining the CCP with the CAPRA-S score yielded consistently predictive outcomes across a range of clinical risk, including low-risk patients.

"The performance of the CCP score in this validation study was excellent," the authors write. "The score provided independent prognostic information after radical prostatectomy and may prove useful in helping guide decisions with respect to adjuvant treatment and in stratifying men for future adjuvant therapy studies."

Several authors disclosed financial ties to genetics firms. Myriad Genetics helped support the study.

Abstract
Full Text (subscription or payment may be required)



Further Reading
Particular gene variants of follicle stimulating hormone (FSH) and its receptor are associated with significantly reduced fertility in men.
Organisms found in the natural microbiota of the vagina, particularly lactobacilli, may influence the virulence of the pathogen that causes trichomoniasis.
The October 2011 U.S. Preventive Services Task Force (USPSTF) recommendation advising against prostate-specific antigen (PSA) testing may be met with resistance by men.
Prostate-specific antigen (PSA) concentrations in midlife can be used to predict the long-term risk of prostate cancer metastasis or death from prostate cancer
Care coordination, enhanced using an electronic health record system, can reduce the number of health care visits needed for the work-up of hematuria.
Toenail selenium, which reflects long-term selenium intake, is associated with a decrease in the risk of advanced prostate cancer, especially during later follow-up.
Urine cytology adds little to the diagnostic value of standard hematuria investigations.
More Reading